PFE - Is Vaxart a Good Coronavirus Stock to Buy?
Companies across the healthcare spectrum are involved in the fight against COVID-19. Some are working on treatments for the disease, while others have rushed to create accurate test kits that can detect traces of the SARS-CoV-2 virus in mere minutes. It's the companies working on vaccines for the disease, however, that have garnered the most attention -- and with good reason. Given how the pandemic has affected our daily lives, our best hope of returning to a semblance of normalcy is arguably the development of an effective vaccine.
One of the companies working on a vaccine for the novel coronavirus is Vaxart (NASDAQ: VXRT). Thanks to its efforts in this fight, the biotech's stock has skyrocketed; even after a recent pullback, it's still up by 1,410% year to date. Meanwhile, the S&P 500 is up by a comparatively meager 4.8% over the same period.
In terms of the progress of its vaccine candidate, Vaxart is far behind the "leaders" in this race. But that doesn't mean investors should overlook this company. Let's take a closer look at why Vaxart could be a winner in the long run.